Navigation Links
Anthera Announces First Quarter 2012 Financial Report and Conference Call
Date:4/27/2012

HAYWARD, Calif., April 27, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, will release its first quarter 2012 financial report after market close on Thursday, May 3, 2012. Anthera will host a conference call at 8:30 am Eastern Time on Friday, May 4, 2012.

Conference Call Access:
Date: Friday, May 4, 2012
Time: 8:30 am Eastern Time

Domestic Dial-in: (877) 312-8807
International Dial-in: (253) 237-1190
Conference ID: 76225935

To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406. The conference ID for the replay is 76225935. The audio replay will be available until May 11, 2012. 

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017  Pennsylvania Secretary of Health Dr. ... marijuana growers/processors and dispensaries are now available on ... Permit applications will be accepted from February 20 ... an important step forward in getting this valuable ... Murphy said. "We,ve developed a thorough application that ...
(Date:1/17/2017)... 17, 2017  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, plans to ... 31, 2016 after the market closes on Wednesday, February ... 5:00 p.m. ET that day to discuss those results. ... (877) 407-8037 or (201) 689-8037.  For 72 hours following ...
(Date:1/17/2017)... 2017  Market Research Future published a Half Cooked Research Report ... to reach USD 33.6 million during the period 2016 to 2022 ... ... Market has been examined as a swiftly growing market and expected ... for endoscopy device in various regions.  The increasing growth in endoscopy ...
Breaking Medicine Technology:
(Date:1/17/2017)... Clemente, CA (PRWEB) , ... January 17, 2017 ... ... Diego County, as well as Palm Desert, is opening a new office in ... Brainsway deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... SightMD – will lecture to primary eye care practitioners on the latest breakthroughs ... the upcoming 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Wettstein Agencies, a ... and business professionals throughout central Colorado, is joining local nonprofit Aurora Warms The ... Warms The Night organization is committed to breaking the cycle of homelessness and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians ... Sandra Lee as keynote speaker for the 34th Annual Miami Breast Cancer Conference®, ... the announcement, PER® president, Phil Talamo, said, “We are delighted to have Sandra ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Today, ... USA Wrestling announced a new agreement as part of a long-term extension of ... 2024 and includes the airing of some of the sport’s premier events exclusively on ...
Breaking Medicine News(10 mins):